Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world’s largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking place June 16-20, 2025, in Denver, Colorado. Psyence BioMed will present on business ethics in a panel session, “We are the Guardrails: Profit with Purpose.” In the role of Chief of Global Impact for Psyence Biomed, the first Nasdaq-listed biopharma with a focus on developing nature-derived (non-synthetic) psilocybin medicine for FDA approval, Gifford works in Washington, DC, to build bridges between research, regulation, and patient care.
To view the full press release, visit https://ibn.fm/qr93E
About Psyence Biomedical Ltd.
Psyence Biomed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. The name “Psyence” merges “psychedelics” and “science,” reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. For more information, visit the company’s website at www.PsyenceBiomed.com.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
Austin, Texas
www.PsychedelicNewsWire.com
512.354.7000 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
